Table 1. Technical details of the CE-FDG-PET-CT.
| CT | Plane | Area scanned | mAs | kV | Speed (s per rotation) | Thickness | FOV (mm) |
|---|---|---|---|---|---|---|---|
| Attenuation correction | Axial | Whole body | 80 | 120 | 0.75 | 4.0 | 600 |
| Diagnostic non-contrast-enhanced | Axial | Whole body | 250–340 | 120 | 0.75 | 4.0 | 350–459 |
| Diagnostic contrast-enhanced | Axial | Whole body | 250–340 | 120 | 0.75 | 4.0 | 350–459 |
| PET | BP | Acquisition time/BP (min) | Iterative reconstruction algorithm | Iterations | Subsets | Axial FOV (mm) | Voxel size (mm3) | Image grid |
|---|---|---|---|---|---|---|---|---|
| 5–7 | 1.5 | LMOSEM 3D | 3 | 33 | 180 | 4 × 4 × 4 | 144 × 144 × 144 |
Abbreviations: BP=bed position; CE-FDG-PET-CT=contrast enhanced-fluorodexossyglucose-positron emission tomography-computed tomography; FOV=field of view; kV=kilovolt; LMOSED 3D=three-dimensional list mode ordered subset expectation maximisation; mAs=milliampere second.
PET data and CT attenuation scans were acquired during shallow free breathing. PET data underwent automatic attenuation correction using attenuation maps generated from attenuation correction CT. Diagnostic non-contrast-enhanced and diagnostic contrast-enhanced scans were acquired during shallow free breathing for the head, neck, pelvis and upper thighs; they were acquired during breath-hold in expiration for the chest and upper abdomen. All patients underwent contrast injection. Iodine-based contrast medium Iomeprol (Iopamiro 370, Bracco Imaging S.p.A., Milan, Italy) was injected intravenously with a power injector (Empower CTA, Acist Medical Solutions, Eden Prairie, MN, USA) at 2 ml s−1, at a fixed dose of 80 ml for patients weighing <80 kg and at 100 ml for those weighing ≥80 kg; scans were started at the end of contrast injection.